Romualdo Barroso-Sousa1,2, Hao Guo3, Piyush Srivastava4, Ted James5, Walter Birch6, Lillian L Siu7, William P Tew8, Sara M Tolaney1. 1. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. 2. Current affiliation: Oncology Center, Hospital Sírio-Libanês, Brasilia-DF, 70200-730, Brazil. 3. Department of Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. 4. Division of Hematology/Oncology, Kaiser Permanente, Walnut Creek, CA 94596, USA. 5. Division of Surgical Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA. 6. Division of Practice Management, American Society of Clinical Oncology, Alexandria, VA 22314, USA. 7. Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, ON M5G 2C1, Canada. 8. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Abstract
Aim: To identify patterns of use and barriers to tumor genomic testing among oncologists. Methods: We surveyed American Society of Clinical Oncology physician members about their use of genomic testing. Results: Among 11,900 members surveyed, a total of 1000 responded to the survey (participation rate, 8.4%). A total of 75% of the respondents included in the analysis reported ordering tests for at least 1-10% of their patients. Practice setting (academic vs community) was only a determinant in the ordering frequency in North America. Regardless of location, academic oncologists were more likely to prescribe medicine in the context of a clinical trial. Access to clinical trials and costs associated with testing were the barriers identified worldwide. Conclusion: There is substantial variation in the use of genomic tools according to region and practice setting; yet, the barriers are similar worldwide.
Aim: To identify patterns of use and barriers to tumor genomic testing among oncologists. Methods: We surveyed American Society of Clinical Oncology physician members about their use of genomic testing. Results: Among 11,900 members surveyed, a total of 1000 responded to the survey (participation rate, 8.4%). A total of 75% of the respondents included in the analysis reported ordering tests for at least 1-10% of their patients. Practice setting (academic vs community) was only a determinant in the ordering frequency in North America. Regardless of location, academic oncologists were more likely to prescribe medicine in the context of a clinical trial. Access to clinical trials and costs associated with testing were the barriers identified worldwide. Conclusion: There is substantial variation in the use of genomic tools according to region and practice setting; yet, the barriers are similar worldwide.
Entities:
Keywords:
genomics; next-generation sequencing; oncology; precision medicine
Authors: Bin Huang; Quan Chen; Derek Allison; Riham El Khouli; Keng Hee Peh; James Mobley; Abigail Anderson; Eric B Durbin; Donald Goodin; John L Villano; Rachel W Miller; Susanne M Arnold; Jill M Kolesar Journal: JCO Precis Oncol Date: 2021-09-29
Authors: Daniel M Sheinson; William B Wong; Craig S Meyer; Stella Stergiopoulos; Katherine T Lofgren; Carlos Flores; Devon V Adams; Mark E Fleury Journal: JAMA Netw Open Date: 2021-12-01
Authors: Eric C Anderson; Alexandra C Hinton; Christine W Lary; Anny T H R Fenton; Andrey Antov; Emily Edelman; Petra Helbig; Kate Reed; Susan Miesfeldt; Christian A Thomas; Michael J Hall; J Scott Roberts; Jens Rueter; Paul K J Han Journal: BMC Cancer Date: 2021-11-25 Impact factor: 4.430